Suivre
Dusan Ruzic
Dusan Ruzic
Adresse e-mail validée de pharmacy.bg.ac.rs
Titre
Citée par
Citée par
Année
In silico methods for design of kinase inhibitors as anticancer drugs
Z Gagic, D Ruzic, N Djokovic, T Djikic, K Nikolic
Frontiers in chemistry 7, 873, 2020
382020
Modulating Protein–Protein Interactions with Visible‐Light‐Responsive Peptide Backbone Photoswitches
L Albert, A Peñalver, N Djokovic, L Werel, M Hoffarth, D Ruzic, J Xu, ...
ChemBioChem 20 (11), 1417-1429, 2019
222019
Quantitative structure-retention relationship of selected imidazoline derivatives on α1-acid glycoprotein column
S Filipic, D Ruzic, J Vucicevic, K Nikolic, D Agbaba
Journal of Pharmaceutical and Biomedical Analysis 127, 101-111, 2016
212016
Combined Ligand and Fragment‐based Drug Design of Selective Histone Deacetylase–6 Inhibitors
D Ruzic, M Petkovic, D Agbaba, A Ganesan, K Nikolic
Molecular Informatics 38 (5), 1800083, 2019
112019
In silico identification of novel 5-HT2A antagonists supported with ligand- and target-based drug design methodologies
M Radan, D Ruzic, M Antonijevic, T Djikic, K Nikolic
Journal of Biomolecular Structure and Dynamics 39 (5), 1819-1837, 2021
72021
Structure-based design of selective histone deacetylase 6 zinc binding groups
LA Alves Avelar, D Ruzic, N Djokovic, T Kurz, K Nikolic
Journal of Biomolecular Structure and Dynamics 38 (11), 3166-3177, 2020
72020
Extending cross metathesis to identify selective HDAC inhibitors: synthesis, biological activities, and modeling
S Bouchet, C Linot, D Ruzic, D Agbaba, B Fouchaq, J Roche, K Nikolic, ...
ACS medicinal chemistry letters 10 (6), 863-868, 2019
62019
Synthesis and biological activity of a cytostatic inhibitor of MLLr leukemia targeting the DOT1L protein
C Bon, Y Si, M Pernak, M Barbachowska, E Levi-Acobas, V Cadet Daniel, ...
Molecules 26 (17), 5300, 2021
42021
An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS‐CoV‐2 Main Protease
N Djokovic, D Ruzic, T Djikic, S Cvijic, J Ignjatovic, S Ibric, K Baralic, ...
Molecular Informatics 40 (5), 2000187, 2021
22021
Anticancer evaluation of the selected tetrahydropyrimidines: 3D-QSAR, cytotoxic activities, mechanism of action, DNA, and BSA interactions
E Milović, J Petronijević, N Joksimović, M Beljkaš, D Ružić, K Nikolić, ...
Journal of Molecular Structure 1257, 132621, 2022
12022
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
D Ruzic, N Djoković, T Srdić-Rajić, C Echeverria, K Nikolic, JF Santibanez
Pharmaceutics 14 (1), 209, 2022
12022
Medicinal chemistry of histone deacetylase inhibitors
ZV D. Ruzic, N. Djokovic, K. Nikolic
Archives of Pharmacy, https://aseestant.ceon.rs/index.php/arhf, 2021
1*2021
Fragment-Based Drug Design of Selective HDAC6 Inhibitors
D Ruzic, N Djokovic, K Nikolic
Protein-Ligand Interactions and Drug Design, 155-170, 2021
12021
Expanding the Accessible Chemical Space of SIRT2 Inhibitors through Exploration of Binding Pocket Dynamics
N Djokovic, D Ruzic, M Rahnasto-Rilla, T Srdic-Rajic, ...
Journal of Chemical Information and Modeling, 2022
2022
Racionalni dizajn, sinteza i in vitro ispitivanja selektivnih inhibitora histon deacetilaze 6
DB Ružić
Univerzitet u Beogradu-Farmaceutski fakultet, 2022
2022
Design of Dual COX-2 and 5-LOX Inhibitors with Iron-Chelating Properties Using Structure-Based and Ligand-Based Methods
J Bošković, D Ružić, O Čudina, K Nikolic, V Dobričić
Letters in Drug Design & Discovery 19 (4), 279-292, 2022
2022
Quinazoline-based analog of adenine as an antidote against MLL-rearranged leukemia cells: synthesis, inhibition assays and docking studies
C Bon, M Barbachowska, N Djokovic, D Ruzic, Y Si, L Soresinetti, C Jallet, ...
Future Medicinal Chemistry 14 (8), 557-570, 2022
2022
Discovery of 1-benzhydryl piperazine-based HDAC inhibitors with anticancer and antimetastatic properties against human breast cancer: synthesis, molecular modeling, in vitro …
D Ruzic, M Petkovic, N Djokovic, J Santibanez, B Ellinger, M Beljkas, ...
2022
3D-QSAR
J Bošković, D Ružić, O Čudina, K Nikolic, V Dobričić
Letters in Drug Design & Discovery 19 (4), 263, 2022
2022
Bistable Photoswitch Allows in Vivo Control of Hematopoiesis
L Albert, J Nagpal, W Steinchen, L Zhang, L Werel, N Djokovic, D Ruzic, ...
ACS Central Science, 2021
2021
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20